2022年12月最新中科院JCR期刊分区表数据（升级版）已经更新，欢迎查询！ 如果您对期刊系统有任何需求或者问题，欢迎反馈给我们。
 |
| 基本信息 | 登录收藏 | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | MOLECULAR CANCER RESEARCH MOL CANCER RES LetPub评分 7.5
50人评分
我要评分
声誉 8.8 影响力 6.5 速度 7.0 | |||||||||||||||||||||||||
| 期刊ISSN | 1541-7786 | 微信扫码收藏此期刊 | ||||||||||||||||||||||||
| E-ISSN | 1557-3125 | |||||||||||||||||||||||||
| 2021-2022最新影响因子 （数据来源于搜索引擎） | 注册或登录后，查看影响因子和历年趋势图 | |||||||||||||||||||||||||
| 2021-2022自引率 | 1.30%注册或登录后，查看自引率趋势图 | |||||||||||||||||||||||||
| h-index | 124 | |||||||||||||||||||||||||
| CiteScore |
| |||||||||||||||||||||||||
| 期刊简介 | Molecular Cancer Research publishes articles describing novel basic cancer research discoveries of broad interest to the field. Studies must be of demonstrated significance, and the journal prioritizes analyses performed at the molecular and cellular level that reveal novel mechanistic insight into pathways and processes linked to cancer risk, development, and/or progression. Areas of emphasis include all cancer-associated pathways (including cell-cycle regulation; cell death; chromatin regulation; DNA damage and repair; gene and RNA regulation; genomics; oncogenes and tumor suppressors; signal transduction; and tumor microenvironment), in addition to studies describing new molecular mechanisms and interactions that support cancer phenotypes. For full consideration, primary research submissions must provide significant novel insight into existing pathway functions or address new hypotheses associated with cancer-relevant biologic questions. | |||||||||||||||||||||||||
| 期刊官方网站 | http://mcr.aacrjournals.org/ | |||||||||||||||||||||||||
| 期刊投稿网址 | http://mcr.msubmit.net/cgi-bin/main.plex | |||||||||||||||||||||||||
| 期刊语言要求 | 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件，不仅能满足MOLECULAR CANCER RESEARCH的语言要求，还能让MOLECULAR CANCER RESEARCH编辑和审稿人得到更好的审稿体验，让稿件最大限度地被MOLECULAR CANCER RESEARCH编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）帮助作者准备稿件，已助力全球15万+作者顺利发表论文。部分发表范例可查看：服务好评 论文致谢 。
提交文稿 | |||||||||||||||||||||||||
| 是否OA开放访问 | No | |||||||||||||||||||||||||
| 通讯方式 | AMER ASSOC CANCER RESEARCH, 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, USA, PA, 19106-4404 | |||||||||||||||||||||||||
| 出版商 | American Association for Cancer Research Inc. | |||||||||||||||||||||||||
| 涉及的研究方向 | 医学-细胞生物学 | |||||||||||||||||||||||||
| 出版国家或地区 | UNITED STATES | |||||||||||||||||||||||||
| 出版语言 | English | |||||||||||||||||||||||||
| 出版周期 | Monthly | |||||||||||||||||||||||||
| 出版年份 | 2002 | |||||||||||||||||||||||||
| 年文章数 | 174注册或登录后，查看年文章数趋势图 | |||||||||||||||||||||||||
| Gold OA文章占比 | 1.49% | |||||||||||||||||||||||||
| 研究类文章占比： 文章 ÷（文章 + 综述） | 90.80% | |||||||||||||||||||||||||
| WOS期刊SCI分区 （ 2021-2022年最新版） | WOS分区等级：2区
| |||||||||||||||||||||||||
| 中科院《国际期刊预警 名单（试行）》名单 | 2023年01月发布的2023版：不在预警名单中 2021年12月发布的2021版：不在预警名单中 2021年01月发布的2020版：不在预警名单中 | |||||||||||||||||||||||||
| 中科院SCI期刊分区 （ 2022年12月最新升级版） | 注册或登录后，查看中科院SCI期刊分区趋势图
| |||||||||||||||||||||||||
| 中科院SCI期刊分区 （ 2021年12月基础版） |
| |||||||||||||||||||||||||
| 中科院SCI期刊分区 （ 2021年12月升级版） |
| |||||||||||||||||||||||||
| 中科院SCI期刊分区 （ 2020年12月旧的升级版） |
| |||||||||||||||||||||||||
| SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月，原SCI撤销合并入SCIE，统称SCIE) Scopus (CiteScore) | |||||||||||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1541-7786%5BISSN%5D | |||||||||||||||||||||||||
| 平均审稿速度 | 网友分享经验： 偏慢,4-8周 | |||||||||||||||||||||||||
| 平均录用比例 | 网友分享经验： 较易 | |||||||||||||||||||||||||
| LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍，平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）后论文在MOLECULAR CANCER RESEARCH顺利发表。
快看看作者怎么说吧：服务好评 论文致谢 | |||||||||||||||||||||||||
| 期刊常用信息链接 |
| |||||||||||||||||||||||||
|
|
| |
| 注册或登录后，查看自引率趋势图 |
| 注册或登录后，查看中科院SCI期刊分区趋势图 |
| 注册或登录后，查看年文章数趋势图 |
| 中国学者近期发表的论文 | |
| 1. | HDAC Inhibition for the Treatment of Epithelioid Sarcoma: Novel Cross Talk Between Epigenetic Components. Author: Lopez G, Song Y, Lam R, Ruder D, Creighton CJ, Bid HK, Bill KL, Bolshakov S, Zhang X, Lev D, Pollock RE. Journal: Mol Cancer Res. 2016 Jan;14(1):35-43. doi: 10.1158/1541-7786.MCR-15-0295. Epub 2015 Sep 22. PubMed |
| 2. | Integrative Analysis Reveals the Transcriptional Collaboration between EZH2 and E2F1 in the Regulation of Cancer-Related Gene Expression. Author: Xu H, Xu K, He HH, Zang C, Chen CH, Chen Y, Qin Q, Wang S, Wang C, Hu S, Li F, Long H, Brown M, Liu XS. Journal: Mol Cancer Res. 2016 Feb;14(2):163-72. doi: 10.1158/1541-7786.MCR-15-0313. Epub 2015 Dec 9. PubMed |
| 3. | The Role of CD44 in Glucose Metabolism in Prostatic Small Cell Neuroendocrine Carcinoma. Author: Li W, Cohen A, Sun Y, Squires J, Braas D, Graeber TG, Du L, Li G, Li Z, Xu X, Chen X, Huang J. Journal: Mol Cancer Res. 2016 Apr;14(4):344-53. doi: 10.1158/1541-7786.MCR-15-0466. Epub 2016 Feb 1. PubMed |
| 4. | Reciprocal Negative Regulation between EGFR and DEPTOR Plays an Important Role in the Progression of Lung Adenocarcinoma. Author: Zhou X, Guo J, Ji Y, Pan G, Liu T, Zhu H, Zhao J. Journal: Mol Cancer Res. 2016 May;14(5):448-57. doi: 10.1158/1541-7786.MCR-15-0480. Epub 2016 Feb 19. PubMed |
| 5. | Deletion or epigenetic silencing of AJAP1 on 1p36 in glioblastoma. Author: Lin N, Di C, Bortoff K, Fu J, Truszkowski P, Killela P, Duncan C, McLendon R, Bigner D, Gregory S, Adamson DC. Journal: Mol Cancer Res. 2012 Feb;10(2):208-17. doi: 10.1158/1541-7786.MCR-10-0109. Epub 2012 Jan 12. PubMed |
| 6. | Migfilin regulates esophageal cancer cell motility through promoting GSK-3β-mediated degradation of β-catenin. Author: He H, Ding F, Li Y, Luo A, Chen H, Wu C, Liu Z. Journal: Mol Cancer Res. 2012 Mar;10(3):273-81. doi: 10.1158/1541-7786.MCR-11-0419. Epub 2012 Jan 13. PubMed |
| 7. | SPINDLIN1 promotes cancer cell proliferation through activation of WNT/TCF-4 signaling. Author: Wang JX, Zeng Q, Chen L, Du JC, Yan XL, Yuan HF, Zhai C, Zhou JN, Jia YL, Yue W, Pei XT. Journal: Mol Cancer Res. 2012 Mar;10(3):326-35. doi: 10.1158/1541-7786.MCR-11-0440. Epub 2012 Jan 18. PubMed |
| 8. | Downregulation of human farnesoid X receptor by miR-421 promotes proliferation and migration of hepatocellular carcinoma cells. Author: Zhang Y, Gong W, Dai S, Huang G, Shen X, Gao M, Xu Z, Zeng Y, He F. Journal: Mol Cancer Res. 2012 Apr;10(4):516-22. doi: 10.1158/1541-7786.MCR-11-0473. Epub 2012 Mar 23. PubMed |
| 9. | Biological functions of cytokeratin 18 in cancer. Author: Weng YR, Cui Y, Fang JY. Journal: Mol Cancer Res. 2012 Apr;10(4):485-93. doi: 10.1158/1541-7786.MCR-11-0222. Epub 2012 Mar 27. PubMed |
| 10. | Overexpression of Aurora-A enhances invasion and matrix metalloproteinase-2 expression in esophageal squamous cell carcinoma cells. Author: Wang X, Lu N, Niu B, Chen X, Xie J, Cheng N. Journal: Mol Cancer Res. 2012 May;10(5):588-96. doi: 10.1158/1541-7786.MCR-11-0416. Epub 2012 Apr 20. PubMed |
|
|
  | |
|
以上SCI期刊相关数据和信息来源于网络，仅供参考。
投稿状态统计： 我要评分： | |
同领域作者分享投稿经验：共0条 （包含回复） |
我来分享 |
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2023 中国: LetPub上海分公司 网站备案号：沪ICP备10217908号-1 
沪公网安备号：31010402006960
增值电信业务经营许可证：沪B2-20211595
礼翰商务信息咨询（上海）有限公司 办公地址：上海市徐汇区漕溪北路88号圣爱大厦2103室
United States: Tel: 1-781-202-9968 Address: 400 5th Ave, Suite 530, Waltham, Massachusetts 02451
安全保密
